336 related articles for article (PubMed ID: 23171508)
1. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
Ribas A; Chesney JA; Gordon MS; Abernethy AP; Logan TF; Lawson DH; Chmielowksi B; Glaspy JA; Lewis K; Huang B; Wang E; Hsyu PH; Gomez-Navarro J; Gerhardt D; Marshall MA; Gonzalez R
J Transl Med; 2012 Nov; 10():236. PubMed ID: 23171508
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH; Antonia S; Sosman J; Kirkwood JM; Gajewski TF; Redman B; Pavlov D; Bulanhagui C; Bozon VA; Gomez-Navarro J; Ribas A
J Clin Oncol; 2009 Mar; 27(7):1075-81. PubMed ID: 19139427
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
Millward M; Underhill C; Lobb S; McBurnie J; Meech SJ; Gomez-Navarro J; Marshall MA; Huang B; Mather CB
Br J Cancer; 2013 May; 108(10):1998-2004. PubMed ID: 23652314
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
[TBL] [Abstract][Full Text] [Related]
7. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
[TBL] [Abstract][Full Text] [Related]
8. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Lipson EJ; Drake CG
Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
Camacho LH
Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
[TBL] [Abstract][Full Text] [Related]
11. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
[TBL] [Abstract][Full Text] [Related]
12. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
13. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
[TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
16. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
17. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
[TBL] [Abstract][Full Text] [Related]
18. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
von Euw E; Chodon T; Attar N; Jalil J; Koya RC; Comin-Anduix B; Ribas A
J Transl Med; 2009 May; 7():35. PubMed ID: 19457253
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
20. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]